Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

77.09
BATS BZX Real-Time Price
As of 3:04pm ET
 -0.36 / -0.46%
Today’s Change
66.93
Today|||52-Week Range
83.58
+5.83%
Year-to-Date
NVS Regular Dividend: NVS will begin trading ex-dividend on 03/01/17 with a $2.7464 dividend payable to shareholders of record as of 03/03/17.
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates
10:27am / Zacks.com - Paid Partner Content
Gilead Sciences Raises Dividend by Double Digits
Feb 22 / GuruFocus News - Paid Partner Content
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, No...
8:15am / Zacks.com - Paid Partner Content
Momenta Pharmaceuticals, Inc. Earnings Take a Back Seat
Feb 22 / MotleyFool.com - Paid Partner Content
Ring the Register With These Upcoming Spinoffs
7:46am / TheStreet.com - Paid Partner Content
ImmunoGen, Inc.: Waiting to Move FORWARD
Feb 21 / MotleyFool.com - Paid Partner Content
J.P. Marvel Investment Advisors, LLC Buys Akamai Technologies, Zayo Group Holdings, A...
Feb 23 / GuruFocus News - Paid Partner Content
Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today
Feb 21 / MotleyFool.com - Paid Partner Content
Here's Why Celgene's Latest Drug Is So Exciting
Feb 23 / MotleyFool.com - Paid Partner Content
Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today
Feb 21 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close77.45
Today’s open77.03
Day’s range76.82 - 77.34
Volume188,351
Average volume (3 months)3,443,539
Market cap$180.0B
Dividend yield3.53%
Data as of 3:04pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)-61.91%
Earnings growth (this year)--
Earnings growth (next 5 years)+4.90%
Revenue growth (last year)-1.90%
P/E ratio27.1
Price/Sales3.61
Price/Book2.44

Competitors

 Today’s
change
Today’s
% change
MRKMerck-0.06-0.09%
PFEPfizer+0.04+0.13%
SNYSanofi+0.14+0.33%
GSKGlaxoSmithKline-0.02-0.05%
Data as of 3:05pm ET, 02/24/2017

Financials

Next reporting dateApril 25, 2017
EPS forecast (this quarter)$1.17
Annual revenue (last year)$48.4B
Annual profit (last year)$6.7B
Net profit margin13.83%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer
Joseph Jimenez
Chief Financial Officer
Harry Kirsch
Corporate headquarters
Basel, Basel-stadt (basle Town)

Forecasts


Search for Jobs